Our Pricing

Does Wegovy Work? Clinical Trial Evidence & UK Results

Published on: June 03, 2026

Does Wegovy work for weight loss UK patients are asking? Clinical evidence from the landmark STEP trials demonstrates that Wegovy (semaglutide 2.4mg) produces significant, sustained weight reduction when combined with lifestyle modifications. At Cured Pharmacy, our UK-registered clinical team helps patients access genuine Wegovy with transparent pricing from £79.00 and comprehensive support throughout treatment.

Clinical Trial Evidence: How Effective Is Wegovy?

Wegovy's efficacy is supported by robust clinical data from the STEP (Semaglutide Treatment Effect in People with obesity) trial programme, which enrolled over 4,500 participants across multiple studies [1]. In the pivotal STEP 1 trial, adults receiving Wegovy 2.4mg weekly achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1].

More impressively, 86.4% of participants on Wegovy achieved at least 5% weight loss — the threshold associated with meaningful health improvements — whilst 69.1% achieved 10% or greater reduction [1]. These results represent some of the most significant weight loss outcomes ever recorded in obesity pharmacotherapy trials.

The STEP 2 trial specifically examined Wegovy in patients with type 2 diabetes, demonstrating an average 9.6% weight reduction alongside improvements in glycaemic control [2]. This dual benefit makes Wegovy particularly valuable for UK patients managing both obesity and metabolic conditions, subject to prescriber assessment.

Does Wegovy Work Long-Term? Sustained Weight Loss Data

One critical question UK patients ask is whether Wegovy maintains effectiveness beyond initial trials. The STEP 4 trial addressed this by randomising participants who had already lost weight on Wegovy to either continue treatment or switch to placebo [3].

Those continuing Wegovy maintained an average additional 7.9% weight reduction, whilst the placebo group regained 6.9% of their body weight over 48 weeks [3]. This 14.8 percentage point difference demonstrates that Wegovy's effects require ongoing treatment — discontinuation typically results in gradual weight regain.

UK real-world data from NHS pilot programmes corroborate these findings, with patients maintaining clinically significant weight loss when adherence to weekly injections remains consistent. Our clinical team at Cured Pharmacy emphasises that Wegovy works most effectively as part of a comprehensive approach including dietary modification and increased physical activity.

What Percentage of Patients Respond to Wegovy?

Response rates vary between individuals, but clinical trials show that approximately 9 in 10 participants achieve meaningful weight loss on Wegovy [1]. Factors influencing response include baseline BMI, adherence to dosing schedule, concurrent lifestyle changes, and individual metabolic differences. Your UK prescriber will monitor your progress and adjust treatment recommendations accordingly.

How Does Wegovy Work? Mechanism of Action Explained

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a naturally occurring hormone involved in appetite regulation and glucose metabolism [4]. When administered weekly via subcutaneous injection, semaglutide activates GLP-1 receptors in multiple tissues.

In the brain, this activation affects areas controlling appetite and food intake, leading to reduced hunger and increased satiety after meals [4]. Simultaneously, Wegovy slows gastric emptying, prolonging feelings of fullness. These combined mechanisms result in spontaneous reduction in caloric intake without the conscious restriction often associated with traditional dieting.

Unlike stimulant-based weight loss medications previously used in the UK, Wegovy does not increase heart rate or blood pressure. Its mechanism targets the underlying hormonal dysregulation often present in obesity, which is why clinical outcomes surpass those achieved through lifestyle modification alone in most patients.

Wegovy Dosing Schedule and Efficacy

Wegovy follows a graduated dosing schedule starting at 0.25mg weekly, escalating over 16-20 weeks to the maintenance dose of 2.4mg [4]. This titration minimises gastrointestinal side effects whilst allowing your body to adapt. Maximum efficacy is typically observed once the full 2.4mg maintenance dose is reached and sustained, which is why patience during the initial escalation phase is essential for optimal results.

Wegovy vs Mounjaro: Comparative Effectiveness for UK Patients

UK patients often ask whether Wegovy or Mounjaro (tirzepatide) produces superior weight loss results. Head-to-head trial data shows that Mounjaro achieves slightly greater average weight reduction — up to 22.5% in the SURPASS-3 trial compared to Wegovy's 14.9% in STEP 1 [5][1].

However, both medications demonstrate clinically significant efficacy, and individual response varies considerably. Mounjaro activates both GIP and GLP-1 receptors (dual agonist), whilst Wegovy targets GLP-1 receptors exclusively (single agonist). This mechanistic difference may account for the variance in trial outcomes, though real-world effectiveness depends on multiple factors including tolerability, adherence, and individual physiology.

At Cured Pharmacy, our UK prescribers assess your medical history, current medications, treatment goals, and budget to recommend the most appropriate option. Both treatments require ongoing use to maintain weight loss, and neither should be considered a short-term solution.

Who Does Wegovy Work Best For? Eligibility and Suitability

Wegovy is licensed in the UK for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea [4]. NICE guidance recommends considering GLP-1 receptor agonists for weight management in this population when lifestyle interventions alone have proven insufficient.

Clinical trials excluded certain populations, so Wegovy may not be suitable if you have a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or diabetic retinopathy [4]. Pregnancy and breastfeeding are contraindications, and women of childbearing potential should use reliable contraception during treatment.

Our online clinical assessment at Cured Pharmacy evaluates your full medical profile to determine suitability. Superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical protocols to ensure safe, appropriate prescribing in accordance with MHRA and GPhC standards.

Does Wegovy Work Without Diet and Exercise?

Whilst Wegovy produces weight loss even without intensive lifestyle modification, clinical trials incorporated reduced-calorie diets and increased physical activity as standard components [1]. Participants received counselling on nutrition and exercise throughout the studies. Real-world effectiveness is maximised when Wegovy is combined with sustainable dietary changes and regular movement, as the medication addresses appetite regulation whilst lifestyle modifications support long-term behaviour change and metabolic health.

Starting Wegovy at Cured Pharmacy: What to Expect

Accessing Wegovy through Cured Pharmacy begins with a free online consultation that takes under three minutes to complete. Our UK-registered prescribers review your medical history, current medications, weight loss goals, and any contraindications to determine clinical suitability.

If approved, your prescription is dispensed from our UK-registered pharmacy (GPhC 9012511) and delivered in 100% discreet packaging. Wegovy is available from £79.00, with transparent pricing displayed before you complete your assessment — no hidden fees or surprise costs at checkout. This represents competitive UK pricing with our lowest price guarantee.

During treatment, you'll follow the graduated dosing schedule, self-administering weekly injections using the pre-filled Wegovy pen. Our clinical team remains available via phone (+44 116 4646009) for questions about injection technique, managing side effects, or adjusting your treatment plan. Most patients begin noticing appetite reduction within the first few weeks, with progressive weight loss accumulating over subsequent months as the dose escalates to maintenance levels.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
3. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
4. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
5. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment, lifestyle modifications, and individual metabolic factors. Clinical trial data represents average outcomes and does not guarantee specific results for any individual patient.